Statins and their increased risk of inducing diabetes

Expert Opinion on Drug Safety

Volumn 14, Issue 12, 2015, Pages 1835-1844

  Agouridis, Aris P ^a,b   Kostapanos, Michael S ^c   Elisaf, Moses S ^b  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

cardiovascular disease; new onset diabetes; statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

DIABETES MELLITUS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NEW ONSET DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SECRETION (PROCESS);

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84951907420     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1096343     Document Type: Review

References (89)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45
2. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-Analysis of statin trials. J Am Coll Cardiol 2014;64:485-94
3. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009;15:479-89
4. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
5. Chang YH, Hsieh MC, Wang CY, et al. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients-A systematic review and meta-Analysis. Rev Diabet Stud 2013;10:157-70
6. Katsiki N, Athyros VG, Karagiannis A, et al. The role of statins in the treatment of type 2 diabetes mellitus: An update. Curr Pharm Des 2014;20:3665-74
7. Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
8. Katsiki N, Rizzo M, Mikhailidis DP, et al. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. Metabolism 2015;64:471-5
9. Athyros VG, Katsiki N, Karagiannis A, et al. Statin potency, LDL receptors and new onset diabetes. Curr Vasc Pharmacol 2014;12:739-40
10. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380:565-71
11. Athyros VG, Elisaf MS, Alexandrides T, et al. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: A post hoc ATTEMPT analysis. Angiology 2012;63:358-66
12. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 2010;375:735-42
13. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244
14. Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009;63:1308-13
15. Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes 2015;6:352-7
16. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013;75:1118-24
17. Cederberg H, Stancakova A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109-17
18. Cederberg H, Laakso M. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]. Diabetologia 2015;58:1962-3
19. Kostapanos MS, Agouridis AP, Elisaf MS. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia 2015;58:1960-1
20. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-Analysis. Diabetes Res Clin Pract 2010;87:98-107
21. Everett BM, Mora S, Glynn RJ, et al. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol 2014;114:1682-9
22. Ong KL, Waters DD, Messig M, et al. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol 2014;113:1593-8
23. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610
24. Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;60:1231-8
25. Ishikawa M, Namiki A, Kubota T, et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006;45:51-5
26. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs rosuvastatin vs simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011;65:1141-8
27. Trajkovic-Arsic M, Kalideris E, Siveke JT. The role of insulin and IGF system in pancreatic cancer. J Mol Endocrinol 2013;50:R67-74
28. Browning DR, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 2007;120:833-43
29. Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-Analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015;241:409-18
30. Macedo AF, Douglas I, Smeeth L, et al. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink. BMC Cardiovasc Disord 2014;14:85
31. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 2011;305:2556-64
32. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Womens Health Initiative. Arch Intern Med 2012;172:144-52
33. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-Analysis. Diabetes Care 2009;32:1924-9
34. Besseling J, Kastelein JJ, Defesche JC, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313:1029-36
35. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7
36. Kruit JK, Brunham LR, Verchere CB, et al. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010;21:178-85
37. Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13
38. Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008;149:5136-45
39. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006;13:329-35
40. Zhou J, Li W, Xie Q, et al. Effects of simvastatin on glucose metabolism in mouse MIN6 cells. J Diabetes Res 2014;2014:376570
41. Bugliani M, Syed F, Masini M, et al. Direct effects of rosuvastatin on pancreatic human beta cells. Acta Diabetol 2013;50:983-5
42. Tsuchiya M, Hosaka M, Moriguchi T, et al. Cholesterol biosynthesis pathway intermediates and inhibitors regulate glucose-stimulated insulin secretion and secretory granule formation in pancreatic beta-cells. Endocrinology 2010;151:4705-16
43. Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: A novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007;56:2328-38
44. Kruit JK, Kremer PH, Dai L, et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010;53:1110-19
45. Yoon JS, Lee HW. Diabetogenic effect of statins: A double-edged sword? Diabetes Metab J 2013;37:415-22
46. Koster JC, Permutt MA, Nichols CG. Diabetes and insulin secretion: the ATPsensitive K+ channel (K ATP) connection. Diabetes 2005;54:3065-72
47. Amin R, Chen HQ, Tannous M, et al. Inhibition of glucose-And calciuminduced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation. J Pharmacol Exp Ther 2002;303:82-8
48. Hianik T, Dlugopolsky J, Masarykova D, et al. Viscoelasticity of BLM from choline plasmalogen, alkylacyl-And diacyl-glycerophosphocholines. Gen Physiol Biophys 1993;12:271-82
49. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001;345:1772-4
50. Bliznakov EG. Diabetes and the role of isoprenoid biosynthesis. FEBS Lett 2002;525:169-70
51. McGuire TF, Xu XQ, Corey SJ, et al. Lovastatin disrupts early events in insulin signaling: A potential mechanism of lovastatins anti-mitogenic activity. Biochem Biophys Res Commun 1994;204:399-406
52. Xu XQ, McGuire TF, Blaskovich MA, et al. Lovastatin inhibits the stimulation of mitogen-Activated protein kinase by insulin in HIRcB fibroblasts. Arch Biochem Biophys 1996;326:233-7
53. Elmendorf JS, Pessin JE. Insulin signaling regulating the trafficking and plasma membrane fusion of GLUT4-containing intracellular vesicles. Exp Cell Res 1999;253:55-62
54. Khan AH, Pessin JE. Insulin regulation of glucose uptake: A complex interplay of intracellular signalling pathways. Diabetologia 2002;45:1475-83
55. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92
56. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-61
57. Takaguri A, Satoh K, Itagaki M, et al. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008;107:80-9
58. Mauser W, Perwitz N, Meier B, et al. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007;564:37-46
59. Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis 2010;212:131-8
60. Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 2014;30:775-84
61. Nowis D, Malenda A, Furs K, et al. Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care 2014;2:e000017
62. Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis. Diabetes 2014;63:3569-71
63. Wen H, Gris D, Lei Y, et al. Fatty acidinduced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408-15
64. Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014;63:3742-7
65. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62:194-204
66. Esser N, LHomme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487-97
67. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med 2012;366:1752-5
68. Gupta A, Dey CS. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 2012;23:3882-98
69. Birnbaum Y, Nanhwan MK, Ling S, et al. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther 2014;28:447-57
70. Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl 2015;16:1-27
71. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-Analysis. JAMA 2009;302:179-88
72. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61
73. Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol 2015;11(6):851-5
74. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014;349:g3743
75. Macedo AF, Taylor FC, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-Analysis. BMC Med 2014;12:51
76. Yan YL, Qiu B, Hu LJ, et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: A systematic review and meta-Analysis. Eur J Clin Pharmacol 2013;69:2001-9
77. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385(9965):351-61
78. Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med 2014;174:1038-45
79. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl 2014;15:1-15
80. Goldstein MR, Mascitelli L. Do statins cause diabetes? Curr Diab Rep 2013;13:381-90
81. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387-97
82. Agouridis AP, Mikhailidis DP. Should we consider ezetimibe to reach even lower LDL-C targets? Curr Med Res Opin 2015;31:459-60
83. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-Analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
84. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-Analysis. Curr Med Res Opin 2011;27:1191-210
85. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5
86. Florentin M, Kostapanos MS, Kei A, et al. Emerging drugs for hyperlipidaemia: An update. Expert Opin Emerg Drugs 2014;19:471-88
87. Milionis H, Liamis G, Elisaf M. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipidlowering therapy. Expert Opin Biol Ther 2015;15:287-98
88. Verma DR, Brinton EA. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies. Rev Cardiovasc Med 2014;15:86-101.quiz
89. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75